Weekly Research Analysts’ Ratings Updates for Myriad Genetics (MYGN)

Several analysts have recently updated their ratings and price targets for Myriad Genetics (NASDAQ: MYGN):

• 8/8/2026 – Myriad Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/4/2026 – Myriad Genetics was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/3/2026 – Myriad Genetics had its price target lowered by Wells Fargo & Company from $5.50 to $3.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Myriad Genetics had its price target lowered by TD Cowen from $6.00 to $4.00. They now have a “hold” rating on the stock.
• 7/30/2026 – Myriad Genetics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/30/2026 – Myriad Genetics was upgraded by Wells Fargo & Company to “hold”.
• 7/14/2026 – Myriad Genetics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/24/2026 – Myriad Genetics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insiders Place Their Bets

In other Myriad Genetics news, Director Rashmi Kumar sold 15,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $4.46, for a total transaction of $66,900.00. Following the completion of the transaction, the director directly owned 171,889 shares of the company’s stock, valued at $766,624.94. This trade represents a 8.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul Bisaro bought 7,500 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $3.69 per share, for a total transaction of $27,675.00. Following the purchase, the director owned 97,441 shares in the company, valued at approximately $359,557.29. This represents a 8.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.90% of the company’s stock.

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.